Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Apixaban not better than enoxaparin for VTE prevention

By News team

An extended course of thromboprophylaxis with apixaban does not give better results than a shorter course with enoxaparin, according to a study published in the New England Journal of Medicine (2011;365:2167).

The ADOPT trial sought to determine the potential of apixaban to prevent venous thromboembolism (VTE) in acutely ill medical patients during hospital stays and in the extended period after their discharge (see Panel).

Researchers found that, over 30 days from the start of treatment, major bleeding events were more common in patients treated with apixaban (0.47 per cent) than those treated with enoxaparin (0.19 per cent) (relative risk 2.58; 95 per cent confidence interval, 1.02–7.24, P=0.04).

At day 30, death related to VTE had occurred in 2.71 per cent of patients receiving apixaban compared with 3.06 per cent of patients receiving enoxaparin (relative risk 0.87, CI 0.62–1.23, P=0.44).

The authors conclude that the results of the trial do not provide evidence for a policy of extended apixaban thromboprophylaxis in a broad population of patients after hospital discharge. However, more precise risk-stratification methods are needed to identify a narrower spectrum of patients who may benefit from extended prophylaxis.

The study was supported by Bristol-Myers Squibb and Pfizer, the marketing authorisation holders of apixaban.

Study method

A total of 6,528 patients who were admitted to hospital following congestive heart failure, acute respiratory failure, acute rheumatic disorder or inflammatory bowel disease were randomly assigned to receive apixaban 2.5mg, administered orally twice-daily for 30 days, or enoxaparin 40mg, administered subcutaneously once-daily during their stay in hospital, for a minimum of six days.

Citation: The Pharmaceutical Journal URI: 11090956

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Apixaban (Eliquis) pack shot

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.